Perimeter Secures FDA PMA for AI-Enabled Claire OCT, Reports Record 2025 Revenues
Summary
Perimeter Medical Imaging AI announced preliminary unaudited Q4 and full-year 2025 financial results, highlighted by record revenues and improved operating performance. Q4 2025 revenue surged 143% year-over-year to $711,000, with full-year revenue reaching $2.3 million, up 172% from 2024. Critically, the company also announced that its Claire™ OCT device, an AI-enabled imaging system for intraoperative breast cancer margin assessment, received FDA Premarket Approval (PMA) in March 2026. This significant regulatory milestone validates Perimeter's technology and strategy, positioning it at the forefront of innovation in breast cancer surgery. The company expects to commercially launch Claire in Q2 2026, which could drive substantial future revenue growth and improve patient outcomes. Investors will be watching the commercial rollout of Claire and continued adoption of its S-Series OCT platform.
At the time of this announcement, PYNKF was trading at $0.32 on OTC in the Life Sciences sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $0.11 to $0.53. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.